Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Thomas' Medicare Appeals Bill Could Cost $1-2 Bil. Over Five Years

This article was originally published in The Gray Sheet

Executive Summary

Legislation designed to accelerate the process for appealing Medicare coverage decisions by the Health Care Financing Administration and its intermediaries could cost as much as $1-2 bil. over five years, according to Rep. Bill Thomas (R-Calif.), sponsor of the legislation and chairman of the House Ways and Means/Health Subcommittee.

You may also be interested in...



Independent Contractors Tapped As Medicare Coverage Appeals Arbitrators

Qualified independent contractors would be used to review Medicare coverage appeals for medical technology under a provision of House Ways and Means/Health Subcommittee Chairman Bill Thomas' (R-Calif.) Medicare drug benefit bill (HR 4680).

Independent Contractors Tapped As Medicare Coverage Appeals Arbitrators

Qualified independent contractors would be used to review Medicare coverage appeals for medical technology under a provision of House Ways and Means/Health Subcommittee Chairman Bill Thomas' (R-Calif.) Medicare drug benefit bill (HR 4680).

Human tumor assay coverage

Laboratory and Diagnostic Services Panel of MCAC convenes Nov. 15 from 8 a.m. to 4 p.m. and Nov. 16 from 8 a.m. to 12 noon in Baltimore to discuss human tumor assays, such as Oncotech's extreme drug resistance test, which previously has been the subject of an admininstrative law judge appeal (1"The Gray Sheet" July 26, p. 12)

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel